ADRB2 and infection: We used propranolol simply as an experimental tool to antagonise β2-AR signalling and it is likely that therapeutic targeting of B cells themselves would provide a superior approach clinically to target infection susceptibility given the potential adverse effects of general β2-AR blockade.